Search results
Results From The WOW.Com Content Network
Biogen was founded in 1978 in Geneva as Biotechnology Geneva by several prominent biologists, including Kenneth Murray from the University of Edinburgh, Phillip Allen Sharp from the Massachusetts Institute of Technology, Walter Gilbert from Harvard University (Gilbert served as CEO during the start-up phase of Biogen), Heinz Schaller from the University of Heidelberg, and Charles Weissmann ...
By Manas Mishra and Mariam Sunny. (Reuters) -Biogen lifted its full-year profit forecast on Thursday due to cost cuts and better-than-expected sales of its various treatments, even as the U.S ...
On Thursday, Sage Therapeutics Inc. (NASDAQ: SAGE) announced that Biogen Inc (NASDAQ: BIIB) had terminated its rights under the collaboration and license agreement with Sage, which was specific to ...
145 912.34 g·mol −1. Aducanumab, sold under the brand name Aduhelm, is a monoclonal antibody designed to treat Alzheimer's disease. [2][3] It is a monoclonal antibody [3][2] that targets aggregated forms (plaque) [4][5] of amyloid beta (Aβ) found in the brains of people with Alzheimer's disease to reduce its buildup. [6][7] It was developed ...
Walter Gilbert was born in Boston, Massachusetts, on March 21, 1932, into a Jewish family, [6] the son of Emma (Cohen), a child psychologist, and Richard V. Gilbert, an economist. [4][7] When Gilbert was seven years old, the family moved to the Washington D.C. area so his father could work under Harry Hopkins on the New Deal brain trust.
James C. “Jim” Mullen (born ca. 1958) is an American business executive. He is the executive chairman at genome editing company Editas Medicine since 2018, where he also served as CEO between 2021 and 2022. [1][2][3] He was formerly the president and CEO of Biogen Idec until he retired effective June 8, 2010. [4]
George A. Scangos was a pharmaceutical executive and former chief executive officer of Vir Biotechnology from 2017 to 2023. Scangos was previously the chief executive officer of Biogen from 2010 to 2016 and of Exelixis from 1996 to 2010. [1][2] Prior to joining industry, Scangos was a professor of biology at Johns Hopkins University. [3][4]
By Khushi Mandowara (Reuters) -Sage Therapeutics has priced the oral postpartum depression (PPD) pill it developed with partner Biogen at $15,900 for a full 14-day course of treatment, the company ...